Resmed (RMD) Current Deferred Revenue (2010 - 2026)

Resmed's Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $179.3 million for Q1 2026.

• Quarterly Current Deferred Revenue rose 11.74% year-over-year to $179.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179.3 million (up 11.74% YoY) and the FY2025 annual result came in at $166.0 million, up 8.83% from the prior year.
• Current Deferred Revenue was $179.3 million for Q1 2026 at Resmed, up from $176.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $179.3 million in Q1 2026 and bottomed at $108.2 million in Q3 2022.
• A 5-year average of $147.3 million and a median of $150.8 million in 2024 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue slipped 3.85% — and 2023, when it surged 35.61%.
• Resmed's Current Deferred Revenue stood at $133.9 million in 2022, then grew by 11.19% to $148.9 million in 2023, then rose by 5.11% to $156.5 million in 2024, then gained by 12.49% to $176.0 million in 2025, then rose by 1.83% to $179.3 million in 2026.
• Business Quant data shows RMD's Current Deferred Revenue at $179.3 million in Q1 2026, $176.0 million in Q4 2025, and $167.8 million in Q3 2025.